Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
about
Foscarnet for suppression of human immunodeficiency virus replication.Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Age-related differences in pharmacokinetics of phosphonoformate in cats.Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitisPenetration of foscarnet into cerebrospinal fluid of AIDS patients.Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.Antiviral therapy: current concepts and practicesA possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma.Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbitsPharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluidAdverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study.Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
P2860
Q33751608-DA266005-8C34-4846-BD3F-5C201B84B0D6Q34034462-831FE32A-C949-4687-A307-482ED97076A5Q34142328-98642E3B-F43B-4427-9AAE-106B11D4E59BQ35254452-43B25792-6B32-4536-A105-5C7D527F7293Q35814373-7BF916DA-A0B7-4F98-9CC0-D40500B07088Q35818751-6748B61B-6A8C-4922-B4BD-C107A3135401Q35894405-56194A7C-EB11-498A-BD94-E74D9F9D9765Q35896783-77811CB6-5260-49F4-B5B5-A1EC37436515Q36070394-42551816-68B9-45A0-8E2C-5DF9DFF56450Q36552426-C646F36D-3109-4BC6-B32C-98E882F09322Q39473244-F4C87736-6BFE-451D-8E2A-49086D460137Q39556643-A688B858-81DB-41EA-BC3B-94D37723A74EQ40284739-978314A0-EBC2-4E53-B1AF-389ACCF0A9DBQ40600560-66C2B9E5-0847-4FC3-87F3-F9F63A68A20EQ41284012-585B68A9-05E8-4157-AB77-99544AAA53EFQ45778365-F2B9D2DB-91CE-4DAF-9D54-ACC126D3B2EEQ46393134-1BD26D14-A7C0-41ED-A750-AF848B68C2ED
P2860
Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@en
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@nl
type
label
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@en
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@nl
prefLabel
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@en
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of foscarnet ...... unodeficiency virus infection.
@en
P2093
P2860
P304
P356
10.1128/AAC.33.7.1023
P407
P577
1989-07-01T00:00:00Z